
|Articles|May 15, 2005
Genetic, molecular anomalies determine RCC therapy
Management of kidney cancer is advancing on several fronts, and this theme of continued progress is well illustrated by research being presented at the AUA annual meeting, said Robert C. Flanigan, MD.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
Choosing salvage therapy after prostate cancer focal ablation
3
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
4
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
5


















